Literature DB >> 3536258

Responders, nonresponders, and placebo responders among children with attention deficit disorder. Importance of a blinded placebo evaluation.

R K Ullmann, E K Sleator.   

Abstract

The responses to methylphenidate of 118 children with attention deficit disorder (ADD) were studied under double-blind conditions. Three distinct types of response to medication and placebo were found, as determined by teacher ratings. One group, called "responders," improved dramatically in attention and hyperactivity ratings on active medication but showed essentially no change from baseline when on placebo. The group called "nonresponders" showed minimal change in ratings on either placebo or medication. The third group, "placebo responders," showed almost as much improvement as the responders on medication, but their ratings were not very different from medication ratings during the placebo trial. The placebo responders, 18 percent of the group, would have been considered responders in a nonplacebo-controlled study. Double-blind placebo evaluation of ADD children can and should be done by practitioners to avoid medicating children who are responding to nonspecific effects of drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3536258     DOI: 10.1177/000992288602501201

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  2 in total

1.  Attention-deficit hyperactivity disorder.

Authors:  D C Meek
Journal:  Can Fam Physician       Date:  1990-09       Impact factor: 3.275

Review 2.  Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Authors:  Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-11-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.